Abstract: Antagonistic small-molecule compounds having a function of inhibiting endosomal Toll-like receptors (TLRs), more specifically, a small-molecule compound for inhibiting TLR3/7/8/9 signaling pathways, a composition for inhibiting Toll-like receptors, containing the compound; and a composition for preventing or treating autoimmune diseases, inflammatory diseases, or viral diseases are disclosed. The novel compound shows very significant results in a systemic lupus erythematosus animal model by not only preventing TNF-? secretion induced by poly I:C (TLR3 agonist), imiquimod (TLR7 agonist), TL8-506 (TLR8 agonist), or ODN2395 (TLR9 agonist), but also inhibiting the production of inflammatory cytokines. This suggests that the compound is also useful for the prevention or treatment of TLR3, TLR7, TLR8 or TLR9-associated autoimmune diseases, inflammatory diseases and viral diseases.

Abstract: A method of manufacturing a composite electrode for an all-solid-state battery includes: preparing a precursor solution by mixing at least one solid electrolyte precursor and at least one polar solvent; stirring the precursor solution; preparing an electrode slurry by adding an active material to the stirred precursor solution; and heat-treating the electrode slurry and obtaining the composite electrode for the all-solid-state battery, wherein the composite electrode for the all-solid-state battery includes: the active material; and a coating layer disposed on the active material and including a solid electrolyte.

Abstract: An air management device may include three independently operated primary impellers 131, 131?, 131?, and drawn-in air is discharged through discharge ports 15?-1, 15?-2, 15?-3 provided in the front plate 15 of the housing 10. Louvers 141, 142, 143 installed downstream of the air flow and discharge ports 15?-1, 15?-2, 15?-3 may be independently opened or closed to provide discharge of the air to the surrounding environment. Further, at least one retractable or pop-up fan may be provided. The air management allows customization of air flow. The housing 10 of the furniture-type air management device may be installed on the floor of the livable space and may have a hexahedron shape that extends from side to side. A bottom inlet 11? may be formed on the bottom plate 11 of the housing 10 facing the floor of the living space above a predetermined distance. The replaceable filter 300 may be installed to filter the air sucked through the bottom inlet 11?, and may be drawn in and out of the housing 10.

Abstract: Disclosed is a method of coating a solid electrolyte of a solid-state battery. The method includes putting an electrode active material and a sulfide-based solid electrolyte into a rotating mixer, operating the rotating mixer to rotate in a first direction while the rotating mixer revolves in a second direction, and coating a surface of the electrode active material with the sulfide-based solid electrolyte in the rotating mixer during the operation of the rotating mixer, to form a solid electrolyte layer on the surface of the electrode active material.

Abstract: In an embodiment a cathode for an all-solid-state battery includes a composite material comprising a cathode active material and a coating layer completely covering a surface of the cathode active material, wherein the coating layer comprises a first solid electrolyte and a second solid electrolyte.

Abstract: Provided is a composition for encapsulating an organic electronic element, comprising an olefin-based resin having at least one reactive functional group, a multifunctional acrylic oligomer, and a monofunctional acrylic oligomer, wherein the monofunctional acrylic oligomer is present in an amount of 7 to 30 parts by weight relative to 100 parts by weight of the olefin-based resin. Also provided are an organic electronic device comprising the composition, and methods for preparing the organic electronic device.

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

Abstract: Disclosed is a semiconductor package comprising a logic die mounted on an interposer substrate, and a memory stack structure disposed side-by-side with the logic die. The memory stack structure includes a buffer die mounted on the interposer substrate, and a plurality of memory dies stacked on the buffer die. The buffer die has a first surface that faces the interposer substrate and a second surface that faces the plurality of memory dies. The number of data terminals on the second surface is greater the number of connection terminals on the first surface.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Abstract: Disclosed is a semiconductor package comprising a logic die mounted on an interposer substrate, and a memory stack structure disposed side-by-side with the logic die. The memory stack structure includes a buffer die mounted on the interposer substrate, and a plurality of memory dies stacked on the buffer die. The buffer die has a first surface that faces the interposer substrate and a second surface that faces the plurality of memory dies. The number of data terminals on the second surface is greater the number of connection terminals on the first surface.

Abstract: A lithium metal halide-based solid electrolyte for an all-solid-state battery with excellent lithium ion conductivity, includes a compound represented by the following Chemical Formula 1. Li6-a(M11-bM2b)X6??[Chemical Formula 1] wherein M1 comprises a group 3 element, a group 4 element or a group 13 element, M2 comprises silicon (Si), germanium (Ge), tin (Sn) or lead (Pb), X comprises chlorine (Cl), bromine (Br) or iodine (I), 0?b?1, and a is a number satisfying the following Mathematical Formula 1.

Abstract: The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient.

Abstract: Disclosed are redistribution substrates and semiconductor packages including the same. The semiconductor package comprises a redistribution substrate, a semiconductor chip mounted on the redistribution substrate, and an inductor structure in the redistribution substrate and electrically connected to the semiconductor chip. The inductor structure includes an outer coil pattern including a plurality of vertical parts and a horizontal part that connects the plurality of vertical parts to each other, and an inner coil pattern between the vertical parts and electrically connected to the outer coil pattern. The horizontal part includes a first conductive layer, and a second conductive layer between the first conductive layer and the inner coil pattern. The second conductive layer has a thickness that is less than a thickness of the first conductive layer.

Abstract: Provided are promoters and a method of producing L-amino acid using the same.

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: A nanofiber membrane includes a polymer nanofiber; and an amphiphilic triblock copolymer bonded to the surface of the polymer nanofiber, the amphiphilic triblock copolymer includes a hydrophobic portion; hydrophilic portions positioned at both ends of the hydrophobic portion; and a low surface energy portion positioned at one end of each of the hydrophilic portions positioned at both ends of the hydrophobic portion, and the hydrophobic portion of the amphiphilic triblock copolymer is bonded to the surface of the polymer nanofiber and the hydrophilic portion and the low surface energy portion are exposed to the outside of the surface of the polymer nanofiber. The membrane simultaneously exhibits hydrophilicity, underwater oleophobicity, and low oil adhesion force, thus has surface segregation properties, and as a result, has an excellent oil permeate flux, exhibits antifouling properties, and can excellently separate oil in water.

Abstract: A nucleic acid molecule comprising a variant inc coding strand is disclosed as a regulator of plasmid copy number. Also disclosed is a replicon comprising the nucleic acid molecule, a promoter, and an origin of replication. Also disclosed is a vector comprising the replicon. Also disclosed is a recombinant microorganism comprising the vector.